Robotic spine surgery technology beside a rising ATEC stock chart, illustrating Alphatec’s insider buying and free-cash-flow turnaround.

🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴

Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?

 

Read entire article

Robotic orthopedic surgical arm beside a plunging ENOV stock chart, illustrating Enovis insider buying, cheap valuation and its eCential robotics bet.

🦴 Enovis (ENOV): CEO Buys the $19 Crash—Is This Falling Knife Finally a Buy? 🤖

Enovis CEO Damien McDonald bought ENOV again after shares collapsed toward $19. Insiders are accumulating, institutions remain heavily invested, analysts see substantial upside and adjusted valuation has fallen below 5x forward earnings. But short interest is high, leverage and integration risks remain—and momentum is dreadful. ENOV may be the ultimate FunStock signal collision.

 

Read entire article